1832 Asset Management L.P. Gilead Sciences, Inc. Transaction History

1832 Asset Management L.P.

$55.8 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$63.15 - $72.88 $1.94 Million - $2.24 Million	-30,738 Reduced 99.61%	120 $8,000
Q1 2024 May 14, 2024	SELL	$71.58 - $87.29 $22,404 - $27,321	-313 Reduced 1.0%	30,858 $2.26 Million
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $543,003 - $615,779	7,411 Added 31.19%	31,171 $2.53 Million
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $1.76 Million - $1.92 Million	23,760 New	23,760 $1.78 Million
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $79,582 - $90,774	1,047 Added 2.29%	46,865 $3.61 Million
Q1 2023 May 12, 2023	BUY	$77.31 - $88.08 $1.59 Million - $1.82 Million	20,612 Added 81.77%	45,818 $3.8 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $433,809 - $622,800	-6,961 Reduced 21.64%	25,206 $2.16 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $32,211 - $36,793	-541 Reduced 1.65%	32,167 $1.98 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $482,712 - $543,678	-8,363 Reduced 20.36%	32,708 $2.02 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $2.38 Million - $2.98 Million	41,071 New	41,071 $2.41 Million
Q4 2021 Feb 15, 2022	SELL	$64.88 - $73.64 $579,573 - $657,826	-8,933 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $604,674 - $652,376	8,933 New	8,933 $638,000
Q1 2021 May 17, 2021	SELL	$60.0 - $68.46 $4.14 Million - $4.72 Million	-68,925 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $1,416 - $1,613	25 Added 0.04%	68,925 $3.92 Million
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $1.91 Million - $2.4 Million	30,800 Added 80.84%	68,900 $4.31 Million
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $578,720 - $672,000	-8,000 Reduced 17.35%	38,100 $2.86 Million
Q1 2020 May 14, 2020	BUY	$62.63 - $80.22 $283,400 - $362,995	4,525 Added 10.88%	46,100 $3.52 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $72,465 - $79,709	-1,176 Reduced 2.75%	41,575 $2.68 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $6,376 - $7,038	102 Added 0.24%	42,751 $2.63 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $2.64 Million - $2.96 Million	42,649 New	42,649 $2.81 Million
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $2.48 Million - $2.78 Million	-39,630 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $1.55 Million - $2.02 Million	25,596 Added 182.39%	39,630 $2.62 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $7.26 Million - $8.04 Million	-101,845 Reduced 87.89%	14,034 $1.24 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $6.44 Million - $7.51 Million	99,238 Added 596.35%	115,879 $8.08 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $6.67 Million - $8.13 Million	-91,605 Reduced 84.63%	16,641 $1.41 Million
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $7.12 Million - $8.36 Million	100,067 Added 1223.46%	108,246 $7.66 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $589,787 - $699,059	8,179	8,179 $843,000

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on 1832 Asset Management L.P. with notifications on news.

Account